An O-glycosylation of fibronectin mediates hepatic osteodystrophy through α4ß1 integrin

Patients with cholestatic liver disease experience increased fracture risk. Higher circulating levels of a fibronectin isoform called oncofetal fibronectin (oFN) were detected in a subset of such patients. Administering this isoform to mice suppresses osteoblast differentiation and diminishes bone m...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Sens-Albert, Carla (VerfasserIn) , Altrock, Eva (VerfasserIn) , Rau, Katrin (VerfasserIn) , Klemis, Verena (VerfasserIn) , Au, Anja von (VerfasserIn) , Nakchbandi, Inaam (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 2017
In: Journal of bone and mineral research
Year: 2016, Jahrgang: 32, Heft: 1, Pages: 70-81
ISSN:1523-4681
DOI:10.1002/jbmr.2916
Online-Zugang:Verlag, Volltext: http://dx.doi.org/10.1002/jbmr.2916
Verlag, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1002/jbmr.2916
Volltext
Verfasserangaben:Carla Sens, Eva Altrock, Katrin Rau, Verena Klemis, Anja von Au, Stefan Pettera, Stephan Uebel, Timo Damm, Sanjay Tiwari, Markus Moser, and Inaam A. Nakchbandi

MARC

LEADER 00000caa a2200000 c 4500
001 1577491572
003 DE-627
005 20230426230630.0
007 cr uuu---uuuuu
008 180711r20172016xx |||||o 00| ||eng c
024 7 |a 10.1002/jbmr.2916  |2 doi 
035 |a (DE-627)1577491572 
035 |a (DE-576)507491572 
035 |a (DE-599)BSZ507491572 
035 |a (OCoLC)1341013480 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Sens-Albert, Carla  |d 1985-  |e VerfasserIn  |0 (DE-588)1139519751  |0 (DE-627)897264894  |0 (DE-576)493346538  |4 aut 
245 1 3 |a An O-glycosylation of fibronectin mediates hepatic osteodystrophy through α4ß1 integrin  |c Carla Sens, Eva Altrock, Katrin Rau, Verena Klemis, Anja von Au, Stefan Pettera, Stephan Uebel, Timo Damm, Sanjay Tiwari, Markus Moser, and Inaam A. Nakchbandi 
246 3 3 |a An O-glycosylation of fibronectin mediates hepatic osteodystrophy through alpha 4 beta 1 integrin 
264 1 |c 2017 
300 |a 12 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Published online: 18 July 2016 
500 |a Gesehen am 11.07.2018 
520 |a Patients with cholestatic liver disease experience increased fracture risk. Higher circulating levels of a fibronectin isoform called oncofetal fibronectin (oFN) were detected in a subset of such patients. Administering this isoform to mice suppresses osteoblast differentiation and diminishes bone mineral density in vivo, suggesting it is responsible for bone loss in cholestatic liver disease. The aim of this study was to define the mechanism by which oFN affects osteoblast function and evaluate possible modifiers in experimental hepatic osteodystrophy. The fibronectin isoform oFN is characterized by the presence of various glycosylations. In line with this, adding oFN that underwent enzymatic O-deglycosylation to osteoblasts normalized nodule formation in vitro. Of three possible O-glycosylation sites in oFN, only a mutation at AA 33 of the variable region or binding of this glycosylated site with an antibody normalized osteoblast differentiation. Because the responsible site is located in the variable region of fibronectin, which binds to α4β1 or α4β7 integrins, these integrins were evaluated. We show that integrin α4β1 mediates the inhibitory effect of oFN both in vitro as well as in vivo. In a hepatic osteodystrophy mouse model, we demonstrate that liver fibrosis is associated with increased circulating oFN and diminished BMD. In addition, trabecular bone loss induced by oFN injection or fibrosis induction could be prevented by either administering an antibody that binds to α4 integrin (PS/2) or the CS1 peptide, which contains a binding site for α4β1 integrin. In summary, oFN inhibits osteoblast activity. This is because of an O-glycosylation in the variable region that results in decreased integrin-mediated signaling. This deleterious effect can be thwarted by binding α4β1 integrin. Thus, we have characterized the defect and the receptor mediating bone loss in patients with hepatic osteodystrophy and evaluated possible therapeutic interventions in a murine model. © 2016 American Society for Bone and Mineral Research. 
534 |c 2016 
650 4 |a FIBRONECTIN 
650 4 |a HEPATIC OSTEODYSTROPHY 
650 4 |a INTEGRIN α4β1 
650 4 |a OSTEOBLAST DIFFERENTIATION 
650 4 |a OSTEOPOROSIS 
700 1 |a Altrock, Eva  |d 1984-  |e VerfasserIn  |0 (DE-588)1139306588  |0 (DE-627)897058607  |0 (DE-576)493229027  |4 aut 
700 1 |a Rau, Katrin  |e VerfasserIn  |0 (DE-588)1162547081  |0 (DE-627)1026680646  |0 (DE-576)507489861  |4 aut 
700 1 |a Klemis, Verena  |e VerfasserIn  |0 (DE-588)1162547847  |0 (DE-627)102668143X  |0 (DE-576)507490231  |4 aut 
700 1 |a Au, Anja von  |d 1983-  |e VerfasserIn  |0 (DE-588)1028385641  |0 (DE-627)730647544  |0 (DE-576)375925694  |4 aut 
700 1 |a Nakchbandi, Inaam  |d 1967-  |e VerfasserIn  |0 (DE-588)142756881  |0 (DE-627)638931053  |0 (DE-576)188363874  |4 aut 
773 0 8 |i Enthalten in  |t Journal of bone and mineral research  |d [Oxford] : Oxford University Press, 1986  |g 32(2017), 1, Seite 70-81  |h Online-Ressource  |w (DE-627)320473716  |w (DE-600)2008867-X  |w (DE-576)098841300  |x 1523-4681  |7 nnas  |a An O-glycosylation of fibronectin mediates hepatic osteodystrophy through α4ß1 integrin 
773 1 8 |g volume:32  |g year:2017  |g number:1  |g pages:70-81  |g extent:12  |a An O-glycosylation of fibronectin mediates hepatic osteodystrophy through α4ß1 integrin 
856 4 0 |u http://dx.doi.org/10.1002/jbmr.2916  |x Verlag  |x Resolving-System  |3 Volltext 
856 4 0 |u https://onlinelibrary.wiley.com/doi/abs/10.1002/jbmr.2916  |x Verlag  |3 Volltext 
951 |a AR 
992 |a 20180711 
993 |a Article 
994 |a 2017 
998 |g 142756881  |a Nakchbandi, Inaam  |m 142756881:Nakchbandi, Inaam  |d 910000  |d 911600  |e 910000PN142756881  |e 911600PN142756881  |k 0/910000/  |k 1/910000/911600/  |p 11  |y j 
998 |g 1028385641  |a Au, Anja von  |m 1028385641:Au, Anja von  |d 910000  |d 911600  |e 910000PA1028385641  |e 911600PA1028385641  |k 0/910000/  |k 1/910000/911600/  |p 5 
998 |g 1162547847  |a Klemis, Verena  |m 1162547847:Klemis, Verena  |d 910000  |d 911600  |e 910000PK1162547847  |e 911600PK1162547847  |k 0/910000/  |k 1/910000/911600/  |p 4 
998 |g 1162547081  |a Rau, Katrin  |m 1162547081:Rau, Katrin  |d 910000  |d 911600  |e 910000PR1162547081  |e 911600PR1162547081  |k 0/910000/  |k 1/910000/911600/  |p 3 
998 |g 1139306588  |a Altrock, Eva  |m 1139306588:Altrock, Eva  |d 910000  |d 911600  |e 910000PA1139306588  |e 911600PA1139306588  |k 0/910000/  |k 1/910000/911600/  |p 2 
998 |g 1139519751  |a Sens-Albert, Carla  |m 1139519751:Sens-Albert, Carla  |d 910000  |d 911600  |e 910000PS1139519751  |e 911600PS1139519751  |k 0/910000/  |k 1/910000/911600/  |p 1  |x j 
999 |a KXP-PPN1577491572  |e 3017291553 
BIB |a Y 
SER |a journal 
JSO |a {"name":{"displayForm":["Carla Sens, Eva Altrock, Katrin Rau, Verena Klemis, Anja von Au, Stefan Pettera, Stephan Uebel, Timo Damm, Sanjay Tiwari, Markus Moser, and Inaam A. Nakchbandi"]},"physDesc":[{"extent":"12 S."}],"recId":"1577491572","relHost":[{"id":{"doi":["10.1002/(ISSN)1523-4681"],"zdb":["2008867-X"],"issn":["1523-4681"],"eki":["320473716"]},"pubHistory":["1.1986 -"],"recId":"320473716","name":{"displayForm":["ASBMR, The American Society for Bone and Mineral Research"]},"physDesc":[{"extent":"Online-Ressource"}],"language":["eng"],"note":["Gesehen am 17.01.24"],"origin":[{"publisherPlace":"[Oxford] ; Washington, DC ; Hoboken, NJ [u.a.]","dateIssuedDisp":"1986-","publisher":"Oxford University Press ; ASBMR ; Wiley","dateIssuedKey":"1986"}],"titleAlt":[{"title":"JBMR Online"}],"type":{"bibl":"periodical","media":"Online-Ressource"},"title":[{"subtitle":"JBMR","title_sort":"Journal of bone and mineral research","title":"Journal of bone and mineral research"}],"part":{"extent":"12","volume":"32","year":"2017","pages":"70-81","text":"32(2017), 1, Seite 70-81","issue":"1"},"disp":"An O-glycosylation of fibronectin mediates hepatic osteodystrophy through α4ß1 integrinJournal of bone and mineral research"}],"id":{"doi":["10.1002/jbmr.2916"],"eki":["1577491572"]},"person":[{"family":"Sens-Albert","display":"Sens-Albert, Carla","role":"aut","given":"Carla"},{"given":"Eva","role":"aut","display":"Altrock, Eva","family":"Altrock"},{"role":"aut","given":"Katrin","family":"Rau","display":"Rau, Katrin"},{"family":"Klemis","display":"Klemis, Verena","role":"aut","given":"Verena"},{"family":"Au","display":"Au, Anja von","role":"aut","given":"Anja von"},{"role":"aut","given":"Inaam","family":"Nakchbandi","display":"Nakchbandi, Inaam"}],"note":["Published online: 18 July 2016","Gesehen am 11.07.2018"],"title":[{"title_sort":"O-glycosylation of fibronectin mediates hepatic osteodystrophy through α4ß1 integrin","title":"An O-glycosylation of fibronectin mediates hepatic osteodystrophy through α4ß1 integrin"}],"origin":[{"dateIssuedDisp":"2017","dateIssuedKey":"2017"}],"titleAlt":[{"title":"An O-glycosylation of fibronectin mediates hepatic osteodystrophy through alpha 4 beta 1 integrin"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"language":["eng"]} 
SRT |a SENSALBERTOGLYCOSYLA2017